Strasbourg biotech appoints ceo
Mark Bloomfield aims to accelerate sales growth at Polyplus-transfection
Bloomfield replaces Frédéric Perraud who continues with Polyplus as chief operating officer and deputy ceo.
Polyplus is planning to accelerate revenue growth by launching reagents and solutions for cell transfection applications, by the commercialisation of ZNA technology through licensing agreements with Sigma-Aldrich and Metabion, as well as geographical sales channel expansion with partners in the US and major European and Asian markets.
Bloomfield has a background in chemistry and joins Polyplus-transfection after more than 15 years in sales and management positions with global companies in the biotechnology tools and analytical instruments markets.
‘I am very much looking forward to using my business experience with the company’s team of scientists, marketers and sales professionals to continue and accelerate its growth,’ said Bloomfield.
You may also like
Pharmaceutical
Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024
Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia
AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026